WFMY News 2's Kevin Kennedy spoke to a doctor who was part of a clinical trial and legislators about what they're doing to ...
In a Phase III trial, Revolution Medicines' daraxonrasib almost doubled the survival length of people with advanced ...
Grant is an M.D./M.B.A. student at Harvard Medical School and Harvard Business School, a researcher at Boston Children’s ...
Good afternoon, and welcome to the Travere Therapeutics Business Update Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nehra, Vice ...
A new daily pill to help with weight loss has been approved by the U.S. Food and Drug Administration (FDA), and it moved ...
The FDA approved a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related ...
Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ...
MedPage Today on MSN
Speeding Up Approvals, Getting More Drugs OTC Among FDA's Top Priorities
"We can do better," commissioner says ...
Replimune Group (NASDAQ:REPL) shares fell roughly 63% following the company’s disclosure that it received a Complete Response ...
Orforglipron is the first new molecular entity cleared under the FDA's Commissioner's National Priority Voucher (CNPV) pilot ...
This isn’t just innovation. It’s protection, accountability, and humanity for everyone involved.”— Jared BootheHOUSTON, ...
FDA's 2023 decision to place 19 peptides on “unsafe” list was supported by numerous documented safety concerns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results